文献速递头痛与眩晕

厄瑞奴单抗在有先兆和无先兆偏头痛患者中的安全性和有效性评估:随机临床试验的二次分析

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
PubMed 文献 · JAMA Neurol · 2022-01-01

该研究为4项双盲安慰剂对照随机临床试验的事后二次分析,纳入2682例成人发作性或慢性偏头痛患者,评估厄瑞奴单抗(70 mg或140 mg每月一次皮下注射)的疗效与安全性。结果显示,无论有无先兆史,厄瑞奴单抗组相比安慰剂组均能更大幅度减少每月偏头痛天数和每月急性偏头痛特异性药物使用天数,且安全性特征与安慰剂相当,支持在该患者群体中使用厄瑞奴单抗。

要点

  • 在有先兆的发作性偏头痛患者中,第12周时厄瑞奴单抗70 mg组和140 mg组相比安慰剂的每月偏头痛天数变化最小二乘均值差分别为-1.1天和-0.9天。
  • 在有先兆的慢性偏头痛患者中,厄瑞奴单抗70 mg组和140 mg组相比安慰剂的每月偏头痛天数变化最小二乘均值差分别为-2.1天和-3.1天。
  • 无论有无先兆史,厄瑞奴单抗组总体安全性特征与安慰剂相似,12周内不良事件未随时间增加。

核心结论

  • 在有先兆和无先兆偏头痛患者中,厄瑞奴单抗治疗均能减少偏头痛频率和每月急性偏头痛特异性药物使用天数,支持其在该患者群体中的有效性和安全性。

研究设计与样本

  • 该研究为4项双盲、安慰剂对照随机临床试验的事后二次分析,试验于2013年8月6日至2019年11月12日在北美、欧洲、俄罗斯和土耳其的治疗中心进行。
  • 共纳入2682例18至65岁发作性或慢性偏头痛成人患者,其中1400例(52.2%)接受至少一剂厄瑞奴单抗70 mg或140 mg,1043例(38.9%)接受安慰剂。
  • 患者平均(标准差)年龄为41.7(11.2)岁,以女性为主(2055例[84.1%])。
  • 厄瑞奴单抗70 mg或140 mg每月一次皮下注射,双盲治疗期后进入开放标签或剂量盲法活性治疗及扩展期。

主要发现

  • 在有先兆的发作性偏头痛患者中,第12周时厄瑞奴单抗70 mg组和140 mg组相比安慰剂的每月偏头痛天数变化最小二乘均值差分别为-1.1(95% CI,-1.7至-0.6)天和-0.9(95% CI,-1.6至-0.2)天。
  • 在有先兆的慢性偏头痛患者中,厄瑞奴单抗70 mg组和140 mg组相比安慰剂的每月偏头痛天数变化最小二乘均值差分别为-2.1(95% CI,-3.8至-0.5)天和-3.1(95% CI,-4.8至-1.4)天。
  • 双盲治疗期间,无论有无先兆史,厄瑞奴单抗组相比安慰剂组的每月偏头痛天数和每月急性偏头痛特异性药物使用天数较基线的降低幅度均更大,且这些降低在扩展期得以维持。
  • 无论有无先兆史,各治疗组总体安全性特征相似,12周内与安慰剂相当,不良事件未随时间增加。

临床怎么用

  • 作者认为,这些发现支持在有先兆和无先兆偏头痛患者中使用厄瑞奴单抗的疗效和安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Migraine with aura may respond differently to therapies than migraine without aura. Individuals with migraine with aura have an elevated vascular risk, necessitating a safety assessment of migraine preventive treatments in this patient subgroup. OBJECTIVE: To assess the efficacy and safety profiles of erenumab in patients with migraine with aura. DESIGN, SETTING, AND PARTICIPANTS: This post hoc secondary analysis evaluated 4 double-blind, placebo-controlled randomized clinical trials that were conducted in treatment centers in North America, Europe, Russia, and Turkey between August 6, 2013, and November 12, 2019. Participants were adults aged 18 to 65 years with episodic migraine or chronic migraine and were randomized to receive either erenumab or placebo. INTERVENTIONS: One or more dose of erenumab (70 mg or 140 mg once per month) or placebo was administered by subcutaneous injection in the double-blind treatment phase and open-label or dose-blinded active treatment, and erenumab, 70 mg or 140 mg, was administered once per month by subcutaneous injection during extension phases. MAIN OUTCOMES AND MEASURES: Efficacy assessments included change from baseline monthly migraine days (MMDs) and monthly acute migraine-specific medication (AMSM) days. Safety end points included patient incidences of adverse events. Subgroups of patients were categorized according to their history of aura. RESULTS: Of the 2682 patients who were randomized in the 4 trials, 1400 (52.2%) received 1 or more dose of erenumab, 70 mg or 140 mg, and 1043 (38.9%) received placebo. Patients had a mean (SD) age of 41.7 (11.2) years and were predominantly women (n = 2055 [84.1%]). Reductions from baseline MMDs and AMSM days were greater in the erenumab than placebo groups in patients with and without a history of aura during the double-blind treatment phase, and these reductions were maintained throughout the extension phases. In patients with episodic migraine and a history of aura, least-squares mean differences in change from baseline MMDs at week 12 were -1.1 (95% CI, -1.7 to -0.6) in those who received erenumab, 70 mg, and -0.9 (95% CI, -1.6 to -0.2) in those who received erenumab, 140 mg, compared with placebo. In patients with chronic migraine with a history of aura, the least-squares mean differences from placebo treatment were -2.1 (95% CI, -3.8 to -0.5) in those who received erenumab, 70 mg, and -3.1 (95% CI, -4.8 to -1.4) in those who received erenumab, 140 mg. Overall safety profiles were similar across treatment groups regardless of aura history and were comparable to that of placebo over 12 weeks, with no increased emergence of adverse events over time. CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of 4 randomized clinical trials showed reduced migraine frequency and AMSM days with erenumab treatment in patients with migraine with and without a history of aura. The findings support the efficacy and safety of using erenumab in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01952574, NCT02456740, NCT02483585, NTCT02066415, and NCT02174861.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ashina M, Goadsby PJ, Dodick DW, et al. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA Neurol. 2022. PMID: 34928306. doi:10.1001/jamaneurol.2021.4678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。